Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
Boudin L, Gonçalves A, Sabatier R, Moretta J, Sfumato P, Asseeva P, Livon D, Bertucci F, Extra JM, Tarpin C, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Sobol H, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Viens P, Eisinger F, Chabannon C. Boudin L, et al. Among authors: houvenaeghel g. Bone Marrow Transplant. 2017 Mar;52(3):498. doi: 10.1038/bmt.2016.291. Epub 2017 Jan 16. Bone Marrow Transplant. 2017. PMID: 28092355 No abstract available.
Overexpression of erb B2 remains a major risk factor in non-metastatic breast cancers treated with high-dose alkylating agents and autologous stem cell transplantation.
Braud AC, Mathoulin Portier MP, Bardou VJ, Bertucci F, Gravis G, Camerlo J, Begue M, Houvenaeghel G, Maraninchi D, Jacquemier J, Viens P. Braud AC, et al. Among authors: houvenaeghel g. Bone Marrow Transplant. 2002 May;29(9):753-7. doi: 10.1038/sj.bmt.1703540. Bone Marrow Transplant. 2002. PMID: 12040472
Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens.
Genre D, Viens P, Bertucci F, Chabannon C, Gravis G, Braud AC, Camerlo J, Houvenaeghel G, Moutardier V, Goncalvez A, Protière C, Bardou VJ, Maraninchi D. Genre D, et al. Among authors: houvenaeghel g. Bone Marrow Transplant. 2002 Jun;29(11):881-6. doi: 10.1038/sj.bmt.1703556. Bone Marrow Transplant. 2002. PMID: 12080351 Clinical Trial.
Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy.
Viret F, Chabannon C, Sainty D, Genre D, Gonçalves A, Arnoulet C, Gravis G, Bertucci F, Houvenaeghel G, Jacquemier J, Bardou VJ, Ladaique P, Braud AC, Maraninchi D, Viens P. Viret F, et al. Among authors: houvenaeghel g. Bone Marrow Transplant. 2003 Dec;32(11):1059-64. doi: 10.1038/sj.bmt.1704283. Bone Marrow Transplant. 2003. PMID: 14625576 Clinical Trial.
Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment.
Bertucci F, Tarpin C, Charafe-Jauffret E, Bardou VJ, Braud AC, Tallet A, Gravis G, Viret F, Gonçalves A, Houvenaeghel G, Blaise D, Jacquemier J, Maraninchi D, Viens P. Bertucci F, et al. Among authors: houvenaeghel g. Bone Marrow Transplant. 2004 May;33(9):913-20. doi: 10.1038/sj.bmt.1704458. Bone Marrow Transplant. 2004. PMID: 15004544
320 results